These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 23965224)

  • 1. PrefHer: finally addressing the preferences of her, too.
    Melichar B
    Lancet Oncol; 2013 Sep; 14(10):914-5. PubMed ID: 23965224
    [No Abstract]   [Full Text] [Related]  

  • 2. Duration of trastuzumab for HER2-positive breast cancer.
    Montemurro F; Aglietta M
    Lancet Oncol; 2013 Jul; 14(8):678-9. PubMed ID: 23764182
    [No Abstract]   [Full Text] [Related]  

  • 3. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.
    Pivot X; Gligorov J; Müller V; Barrett-Lee P; Verma S; Knoop A; Curigliano G; Semiglazov V; López-Vivanco G; Jenkins V; Scotto N; Osborne S; Fallowfield L;
    Lancet Oncol; 2013 Sep; 14(10):962-70. PubMed ID: 23965225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of adjuvant trastuzumab: shorter beats longer.
    Joensuu H
    Lancet; 2013 Sep; 382(9897):1010-1. PubMed ID: 23871493
    [No Abstract]   [Full Text] [Related]  

  • 5. Intrathecal trastuzumab: dose matters.
    Hofer S; Mengele K; Stemmler HJ; Schmitt M; Pestalozzi B
    Acta Oncol; 2012 Sep; 51(7):955-6. PubMed ID: 22524214
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab therapy for the metastatic patient: does the primary match?
    Leyland-Jones B
    Ann Oncol; 2002 Jul; 13(7):993-4. PubMed ID: 12176776
    [No Abstract]   [Full Text] [Related]  

  • 7. Subcutaneous trastuzumab (Herceptin). Ready to use, but more serious adverse effects than intravenous (IV) trastuzumab.
    Prescrire Int; 2015 Apr; 24(159):93. PubMed ID: 25941697
    [No Abstract]   [Full Text] [Related]  

  • 8. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
    Kurosumi M
    Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
    [No Abstract]   [Full Text] [Related]  

  • 9. The promise of antibody-drug conjugates.
    Teicher BA; Doroshow JH
    N Engl J Med; 2012 Nov; 367(19):1847-8. PubMed ID: 23134386
    [No Abstract]   [Full Text] [Related]  

  • 10. HER2-positive breast cancer: a new piece of the puzzle.
    Gnant M; Bartsch R; Steger GG
    Lancet Oncol; 2014 Jun; 15(7):668-9. PubMed ID: 24793817
    [No Abstract]   [Full Text] [Related]  

  • 11. Trastuzumab in breast cancer.
    Banna GL; Santoro A
    N Engl J Med; 2006 Feb; 354(6):640-4; author reply 640-4. PubMed ID: 16470951
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pertuzumab+trastuzumab+DTX therapy].
    Maejima A; Tamura K
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():553-7. PubMed ID: 25831821
    [No Abstract]   [Full Text] [Related]  

  • 13. How low should we go? The search for balance in management of small human epidermal growth factor receptor 2-positive breast cancers.
    Reeder-Hayes KE; Carey LA
    J Clin Oncol; 2014 Jul; 32(20):2122-4. PubMed ID: 24888811
    [No Abstract]   [Full Text] [Related]  

  • 14. Trastuzumab faces trials, clinical and otherwise.
    Tuma RS
    J Natl Cancer Inst; 2006 Mar; 98(5):296-8. PubMed ID: 16507822
    [No Abstract]   [Full Text] [Related]  

  • 15. [Pertuzumab (PERJETA(®) intravenous infusion 420 mg/14 mL): pharmacological properties and clinical development overview].
    Myobudani H; Ushiyama N; Ichinose R; Takasuka T
    Nihon Yakurigaku Zasshi; 2014 Feb; 143(2):95-102. PubMed ID: 24531903
    [No Abstract]   [Full Text] [Related]  

  • 16. HER2-positive breast cancer, intrinsic subtypes, and tailoring therapy.
    Ellis MJ
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25139535
    [No Abstract]   [Full Text] [Related]  

  • 17. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.
    Webster R; Palaniappan N; Abraham J; Bertelli G; Jasani B; Barrett-Lee P
    Clin Oncol (R Coll Radiol); 2010 Dec; 22(10):894. PubMed ID: 20708911
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination trastuzumab and chemotherapy may have a role in women with small, node-negative, human epidermal growth factor receptor 2-positive breast cancer.
    McArthur HL; Morris PG; Hudis CA
    J Clin Oncol; 2015 Jan; 33(1):124-5. PubMed ID: 25403210
    [No Abstract]   [Full Text] [Related]  

  • 20. POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer.
    Goel S; Winer EP
    Oncology (Williston Park); 2015 Nov; 29(11):797-8, 802. PubMed ID: 26573058
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.